Research results demonstrated that Tyrzepatide (product name Maunjaro, Lilly Korea), a class of GLP-1/GIP receptor agonists for the treatment of diabetes and obesity, has a blood pressure suppressing effect.
A research team from the University of Texas Southwestern Hospital in the United States published research results in Hypertension, an international journal in the field of hypertension, showing that systolic blood pressure was significantly reduced in obese patients using tirzepatide.
The subjects of this study were 600 obese adults (average age 46 years, average BMI 37.4, 67% women). They were randomly assigned to the placebo group (155 people) and the tirzepatide 5 mg (145 people), 10 mg (152 people) and 15 mg (148 people) groups, and changes in mean systolic blood pressure were observed.
As a result of the comparison up to week 36, compared to the placebo group, there was a decrease of 7.4 mmHg in the tirzepatide 5 mg group, 10.6 mm Hg in the 10 mg group and 8 mm Hg in the 15 mg group. This effect lasted not only during the day but also at night. According to the research team, systolic blood pressure at night rather than during the day is a stronger risk factor for cardiovascular disease-related death.
Regarding this effect, the research team said: “It is unclear whether it is due to tirzepatide or weight loss,” but “the degree of hypotension is comparable to the effect of several blood pressure drugs,” they said in a press release from the American Heart Association (AHA).
Dr. Michael Hall of the University of Mississippi Hospital, who was not involved in the study, commented on the results of this study by saying: “New treatments for obesity such as tirzepatide not only reduce weight, but also improve cardiovascular metabolism such as hypertension, type 2 diabetes and dyslipidemia that accompany obesity: “It is encouraging to see that it significantly improves system complications,” he said.
Dr. Hall further stated, “Because most obesity-related complications increase the risk of cardiovascular disease, strategies to suppress them may reduce the risk of cardiovascular incidents,” adding, “To explain the long-term effects of tirzepatide on heart diseases such as myocardial infarction and heart failure, “more research is needed to determine how blood pressure changes when treatment is stopped,” he stressed.
Meanwhile, this research was supported by Eli Lilly, which developed tirzepatide.
#diabetes #obesity #tirzepatide #suppresses #blood #pressure
.jpg?fit=300%2C300&ssl=1)
